Cabometyx in combination with Opdivo reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40-0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx in combination with Opdivo, median progression-free survival (PFS), the trial's primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41-0.64], p < 0.0001).
In addition, Cabometyx in combination with Opdivo demonstrated a superior objective response rate, with twice as many patients responding compared to sunitinib (56% vs. 27%; p
(C) 2020 Electronic News Publishing, source